Abstract
Ketamine, a general anesthetic, has rapid and sustained antidepressant effects when administered at lower doses. Anesthetic levels of ketamine reduce excitatory transmission by binding deep into the pore of NMDA receptors where it blocks current influx. In contrast, the molecular targets responsible for antidepressant levels of ketamine remain controversial. We used electrophysiology, structure-based mutagenesis, and molecular and kinetic modeling to investigate the effects of ketamine on NMDA receptors across an extended range of concentrations. We report functional and structural evidence that, at nanomolar concentrations, ketamine interacts with membrane-accessible hydrophobic sites on NMDA receptors, which are distinct from the established pore-blocking site. These interactions stabilize receptors in pre-open states and produce an incomplete, voltage- and pH-dependent reduction in receptor gating. Notably, this allosteric inhibitory mechanism spares brief synaptic-like receptor activations and preferentially reduces currents from receptors activated tonically by ambient levels of neurotransmitters. We propose that the hydrophobic sites we describe here account for clinical effects of ketamine not shared by other NMDA receptor open-channel blockers such as memantine and represent promising targets for developing safe and effective neuroactive therapeutics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Data availability
Structures and trajectories were deposited in Zenodo https://zenodo.org/records/10711149. Requests for further information, resources, or reagents should be directed to and will be fulfilled by the corresponding author (GKP).
References
Kurdi MS, Theerth KA, Deva RS. Ketamine: current applications in anesthesia, pain, and critical care. Anesth Essays Res. 2014;8:283–90.
Anis NA, Berry SC, Burton NR, Lodge D. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate. Br J Pharmacol. 1983;79:565–75.
Snell LD, Johnson KM. Antagonism of NMDA-induced transmitter release in the rat striatum by phencyclidine-like drugs and its relationship to turning behavior. J Pharmacol Exp Ther. 1985;235:50–57.
Chou TH, Epstein M, Michalski K, Fine E, Biggin PC, Furukawa H. Structural insights into binding of therapeutic channel blockers in NMDA receptors. Nat Struct Mol Biol. 2022;29:507–18.
Song X, Jensen MO, Jogini V, Stein RA, Lee CH, McHaourab HS, et al. Mechanism of NMDA receptor channel block by MK-801 and memantine. Nature. 2018;556:515–9.
Zhang Y, Ye F, Zhang T, Lv S, Zhou L, Du D, et al. Structural basis of ketamine action on human NMDA receptors. Nature. 2021;596:301–5.
Zanos P, Moaddel R, Morris PJ, Riggs LM, Highland JN, Georgiou P, et al. Ketamine and ketamine metabolite pharmacology: insights into therapeutic mechanisms. Pharmacol Rev. 2018;70:621–60.
Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry. 2000;47:351–4.
Krystal JH, Abdallah CG, Sanacora G, Charney DS, Duman RS. Ketamine: a paradigm shift for depression research and treatment. Neuron. 2019;101:774–8.
Zarate CA Jr., Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63:856–64.
Skolnick P, Popik P, Trullas R. Glutamate-based antidepressants: 20 years on. Trends Pharmacol Sci. 2009;30:563–9.
Kavalali ET, Monteggia LM. How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol. 2015;20:35–39.
Zarate CA Jr., Singh JB, Quiroz JA, De Jesus G, Denicoff KK, Luckenbaugh DA, et al. A double-blind, placebo-controlled study of memantine in the treatment of major depression. Am J Psychiatry. 2006;163:153–5.
Johnson JW, Glasgow NG, Povysheva NV. Recent insights into the mode of action of memantine and ketamine. Curr Opin Pharmacol. 2015;20:54–63.
Kotermanski SE, Johnson JW. Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer’s drug memantine. J Neurosci. 2009;29:2774–9.
Dravid SM, Erreger K, Yuan H, Nicholson K, Le P, Lyuboslavsky P, et al. Subunit-specific mechanisms and proton sensitivity of NMDA receptor channel block. J Physiol. 2007;581:107–28.
Parsons CG, Panchenko VA, Pinchenko VO, Tsyndrenko AY, Krishtal OA. Comparative patch-clamp studies with freshly dissociated rat hippocampal and striatal neurons on the NMDA receptor antagonistic effects of amantadine and memantine. Eur J Neurosci. 1996;8:446–54.
MacDonald JF, Bartlett MC, Mody I, Pahapill P, Reynolds JN, Salter MW, et al. Actions of ketamine, phencyclidine and MK-801 on NMDA receptor currents in cultured mouse hippocampal neurones. J Physiol. 1991;432:483–508.
Popescu G, Auerbach A. Modal gating of NMDA receptors and the shape of their synaptic response. Nat Neurosci. 2003;6:476–83.
Borschel WF, Myers JM, Kasperek EM, Smith TP, Graziane NM, Nowak LM, et al. Gating reaction mechanism of neuronal NMDA receptors. J Neurophysiol. 2012;108:3105–15.
Maki BA, Cummings KA, Paganelli MA, Murthy SE, Popescu GK. One-channel cell-attached patch-clamp recording. J Vis Exp. 2014:51629 https://doi.org/10.3791/51629.
Cummings KA, Iacobucci GJ, Popescu GK. Extracting rate constants for NMDA receptor gating from one-channel current recordings. In: Popescu GK (ed). Ionotropic Glutamate Receptor Technologies, vol. 106. Springer New York2016, pp 273-99.
Kussius CL, Kaur N, Popescu GK. Pregnanolone sulfate promotes desensitization of activated NMDA receptors. J Neurosci. 2009;29:6819–27.
Popescu G, Robert A, Howe JR, Auerbach A. Reaction mechanism determines NMDA receptor response to repetitive stimulation. Nature. 2004;430:790–3.
Popescu G. Principles of N-methyl-D-aspartate receptor allosteric modulation. Mol Pharmacol. 2005;68:1148–55.
Chou TH, Tajima N, Romero-Hernandez A, Furukawa H. Structural basis of functional transitions in mammalian NMDA receptors. Cell. 2020;182:357–71.e313.
Iacobucci GJ, Wen H, Helou M, Liu B, Zheng W, Popescu GK. Cross-subunit interactions that stabilize open states mediate gating in NMDA receptors. Proc Natl Acad Sci USA. 2021;118:e2007511118.
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31:455–61.
Vanommeslaeghe K, Raman EP, MacKerell AD Jr. Automation of the CHARMM General Force Field (CGenFF) II: assignment of bonded parameters and partial atomic charges. J Chem Inf Model. 2012;52:3155–68.
Ion BF, Wells MM, Chen Q, Xu Y, Tang P. Ketamine inhibition of the pentameric ligand-gated ion channel GLIC. Biophys J. 2017;113:605–12.
Jo S, Kim T, Iyer VG, Im W. CHARMM-GUI: a web-based graphical user interface for CHARMM. J Comput Chem. 2008;29:1859–65.
Lee J, Cheng X, Swails JM, Yeom MS, Eastman PK, Lemkul JA, et al. CHARMM-GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM simulations using the CHARMM36 additive force field. J Chem Theory Comput. 2016;12:405–13.
Lee CH, Lu W, Michel JC, Goehring A, Du J, Song X, et al. NMDA receptor structures reveal subunit arrangement and pore architecture. Nature. 2014;511:191–7.
Nosé S. A molecular dynamics method for simulations in the canonical ensemble. Mol Phys. 1984;52:255–68.
Hoover WG. Canonical dynamics: equilibrium phase-space distributions. Phys Rev A Gen Phys. 1985;31:1695–7.
Parrinello M, Rahman A. Polymorphic transitions in single crystals: a new molecular dynamics method. J Appl Phys 1981;52:7182–90.
Darden T, York D, Pedersen L. Particle mesh Ewald: An Nlog(N) method for Ewald sums in large systems. J Chem Phys. 1993;98:10089–92.
Hess B, Bekker H, Berendsen HJC, Fraaije JG EM. LINCS: A linear constraint solver for molecular simulations. J Comp Chem 1998;18:1463–72.
Pronk S, Pall S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, et al. GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit. Bioinformatics. 2013;29:845–54.
Klauda JB, Venable RM, Freites JA, O’Connor JW, Tobias DJ, Mondragon-Ramirez C, et al. Update of the CHARMM all-atom additive force field for lipids: validation on six lipid types. J Phys Chem B. 2010;114:7830–43.
Huang J, MacKerell AD Jr. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J Comput Chem. 2013;34:2135–45.
Jorgensen W, Chandrasekhar J, Madura J. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1983;79:926–35.
Yang M, Bo Z, Xu T, Xu B, Wang D, Zheng H. Uni-GBSA: an open-source and web-based automatic workflow to perform MM/GB(PB)SA calculations for virtual screening. Br Bioinf. 2023;24:bbad218.
Deuflhard P, Hermans J, Leimkuhler B, Mark AE, Reich S, Skeel RD, (eds). Steered molecular dynamics. Proceedings of the Computational Molecular Dynamics: Challenges, Methods, Ideas; 1999// 1999; Berlin, Heidelberg. Springer Berlin Heidelberg.
Bonomi M, Branduardi D, Bussi G, Camilloni C, Provasi D, Raiteri P, et al. PLUMED: a portable plugin for free-energy calculations with molecular dynamics. Comput Phys Commun. 2009;180:1961–72.
Tribello GA, Bonomi M, Branduardi D, Camilloni C, Bussi G. PLUMED 2: new feathers for an old bird. Comput Phys Commun. 2014;185:604–13.
Bonomi M, Bussi G, Camilloni C, Tribello GA, Banáš P, Barducci A, et al. Promoting transparency and reproducibility in enhanced molecular simulations. Nature Methods. 2019;16:670–3.
Humphrey W, Dalke A, Schulten K. VMD: Visual molecular dynamics. J Mol Graph. 1996;14:33–38.
Laskowski RA, Swindells MB. LigPlot+: multiple ligand-protein interaction diagrams for drug discovery. J Chem Inf Model. 2011;51:2778–86.
Traynelis SF, Hartley M, Heinemann SF. Control of proton sensitivity of the NMDA receptor by RNA splicing and polyamines. Science. 1995;268:873–6.
Maki BA, Popescu GK. Extracellular Ca(2+) ions reduce NMDA receptor conductance and gating. J Gen Physiol. 2014;144:379–92.
Liu H-T, Hollmann MW, Liu W-H, Hoenemann CW, Durieux ME. Modulation of NMDA receptor function by ketamine and magnesium: part I. Anesth Analg. 2001;92:1173–81.
Orser BA, Pennefather PS, MacDonald JF. Multiple mechanisms of ketamine blockade of N-methyl-D-aspartate receptors. Anesthesiology. 1997;86:903–17.
MacDonald JF, Miljkovic Z, Pennefather P. Use-dependent block of excitatory amino acid currents in cultured neurons by ketamine. J Neurophysiol. 1987;58:251–66.
Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 1977;69:497–515.
Wilcox MR, Nigam A, Glasgow NG, Narangoda C, Phillips MB, Patel DS, et al. Inhibition of NMDA receptors through a membrane-to-channel path. Nat Commun. 2022;13:4114.
Abbott JA, Popescu GK. Hydroxynorketamine blocks N-Methyl-d-Aspartate receptor currents by binding to closed receptors. Mol Pharmacol. 2020;98:203–10.
Ebert B, Mikkelsen S, Thorkildsen C, Borgbjerg FM. Norketamine, the main metabolite of ketamine, is a non-competitive NMDA receptor antagonist in the rat cortex and spinal cord. Eur J Pharmacol. 1997;333:99–104.
Zhang JC, Li SX, Hashimoto KR. (-)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine. Pharmacol Biochem Behav. 2014;116:137–41.
Zanos P, Moaddel R, Morris PJ, Georgiou P, Fischell J, Elmer GI, et al. NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature. 2016;533:481–6.
Iacobucci GJ, Popescu GK. NMDA receptors: linking physiological output to biophysical operation. Nat Rev Neurosci. 2017;18:236–49.
Iacobucci GJ, Popescu GK. Kinetic models for activation and modulation of NMDA receptor subtypes. Curr Opin Physiol. 2018;2:114–22.
Geiger Z, VanVeller B, Lopez Z, Harrata AK, Battani K, Wegman-Points L, et al. Determination of diffusion kinetics of ketamine in brain tissue: implications for in vitro mechanistic studies of drug actions. Front Neurosci. 2021;15:678978.
Yao L, Rong Y, Ma X, Li H, Deng D, Chen Y, et al. Extrasynaptic NMDA receptors bidirectionally modulate intrinsic excitability of inhibitory neurons. J Neurosci. 2022;42:3066–79.
Amico-Ruvio SA, Murthy SE, Smith TP, Popescu GK. Zinc effects on NMDA receptor gating kinetics. Biophys J. 2011;100:1910–8.
Cummings KA, Popescu GK. Glycine-dependent activation of NMDA receptors. J Gen Physiol. 2015;145:513–27.
Iacobucci GJ, Liu B, Wen H, Sincox B, Zheng W, Popescu GK. Complex functional phenotypes of NMDA receptor disease variants. Mol Psychiatry 2022; 27:5113–23.
Acknowledgements
We thank James Hitt for initiating this project, and Lynn Ziegler for technical assistance.
Funding
GKP (R35NS132248, R01MH118298, and R01NS108750) and JAA (5T32GM099607).
Author information
Authors and Affiliations
Contributions
JAA (whole-cell electrophysiology data collection and analyses, model validation, editing). HW (molecular simulations investigation, analyses, and visualization, and editing). BL (whole-cell and single-channel data collection and analyses). SVG (single-channel data collection and curation). GJI (single-channel and whole-cell data analysis, kinetic modeling and simulations, model validation, visualization, and editing). WZ (conceptualization, supervision, and editing). GKP (conceptualization, supervision, data analyses, integration, and writing).
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
All experiments were performed in accordance with the policies, guidelines and regulations in effect at the University at Buffalo, SUNY and the Research Foundation of SUNY. This research has not involved vertebrate animals or human subjects.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Abbott, J.A., Wen, H., Liu, B. et al. Allosteric inhibition of NMDA receptors by low dose ketamine. Mol Psychiatry (2024). https://doi.org/10.1038/s41380-024-02729-9
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41380-024-02729-9